Abstract 1745P
Background
Treatment abandonment (TA) is a major challenge in cancer care leading to poor outcomes and wastage of resources. Reasons for TA are multi-factorial and country specific. Understanding these complexities is the first step toward developing effective strategies for the prevention of TA. Insights and experiences of healthcare workers (HCWs) can provide valuable information about the factors contributing to TA; hence we conducted a qualitative study to understand the issues.
Methods
The participants were purposively selected, experienced HCWs (N=30) treating cancer patients from high-volume cancer centres nationwide. In-depth interviews (semi-structured, open-ended) were conducted by a person trained and experienced in qualitative interviews to understand the perspectives of HCWs on TA among adult cancer patients. We used the grounded theory approach to thematically analyze the data using inductive analysis.
Results
The HCWs (oncologists=17, nurses=6, psycho-oncologists=3, counselors=4) were selected from 9 states of India representing all geographical regions and working in both private (paid services, N= 14) and government (free services, N=16) sectors. The average duration of the interview was 30 minutes, and the reasons for TA perceived by the HCWs were classified under 6 themes: 1) Socio-demographic, 2) Patient-specific, 3) Clinical, 4) Psychological, 5) Health system related, and 6) Economic factors. Catastrophic health expenditure, direct medical and/or non-medical costs, indirect medical costs, poor socio-economic status, lack of specific knowledge about disease and treatment, poor patient-provider communication, accessibility, psychological distress, and toxicities of treatment were the common reasons for TA cited by the HCWs.
Conclusions
The study is one of the first studies reporting on HCWs’ perspective on TA among cancer patients in India. In addition to well-known socio-economic factors, this study identified important themes such as lacunae in communication and psychological issues (e.g., distress) causing TA. The results of this study will help plan quantitative research into the complex issues of TA and interventions to counter the problem.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
P. Ganesan.
Funding
Indian Council of Medical Research-ICMR, New Delhi, India.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1890P - Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)
Presenter: Christopher Darr
Session: Poster session 23
1891P - Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma
Presenter: Renee Saliby
Session: Poster session 23
1892P - A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)
Presenter: Rana McKay
Session: Poster session 23
1895P - Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)
Presenter: Sara Elena Rebuzzi
Session: Poster session 23
1896P - Clinical management and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab+ipilimumab (N+I): A real-world study
Presenter: Tom Geldart
Session: Poster session 23
1897P - Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Presenter: Francesco Massari
Session: Poster session 23
1899P - Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab + nivolumab (ipi+nivo) vs. PD-1/L1 inhibitor (PDI) + tyrosine kinase inhibitor (TKI)
Presenter: Georges Gebrael
Session: Poster session 23
1900P - Role of cytoreductive nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the national cancer database (2004-2020)
Presenter: ALINA BASNET
Session: Poster session 23